Medpace Holdings Affirms FY2026 GAAP EPS Guidance of $16.68-$17.50 vs $17.12 Est; Affirms FY2026 Sales Guidance of $2.755B-$2.855B vs $2.808B Est

Benzinga Newsdesk www.benzinga.com Negative 52.8%

Neg 52.8% Neu 0% Pos 0%

Medpace Holdings (NASDAQ:MEDP) affirms FY2026 GAAP EPS guidance from $16.68-$17.50 to $16.68-$17.50 vs $17.12 analyst estimate. Affirms FY2026 sales outlook from $2.755 billion-$2.855 billion to $2.755 billion-$2.855 billion vs $2.808 billion estimate.